Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer. Sledge GW, Xiu J, Fuqua S, Ribeiro JR, et al. Clin Cancer Res 2026 Oct 13. doi: 10.1158/1078-0432.CCR-26-2215.

Read + Share

Amedeo Smart

Independent Medical Education

Sledge GW, Xiu J, Fuqua S, Ribeiro JR, et al. Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer. Clin Cancer Res 2026 Oct 13. doi: 10.1158/1078-0432.CCR-26-2215.
PMID: 42868272